
AcelRx Pharmaceuticals (ACRX) shares rose strongly in trading today. The company received initial coverage from Credit Suisse, with an outperform rating and $7 price target. ACRX recently received FDA approval in late 2018 for its powerful opioid DSUVIA. The company insists that it will tightly regulate the distribution and dosage so as to avoid patients becoming addicted to the drug. Here’s a recap.